@article{Chowdary_P-2023_151798,
title = {Nebulized Recombinant Tissue Plasminogen Activator (rt-PA) for Acute COVID-19-Induced Respiratory Failure: An Exploratory Proof-of-Concept Trial},
author = {Chowdary, P. and Agarwal, B. and Peralta, M. and Bhagani, S. and Lee, S. and Goldring, J. and Lipman, M. and Waqif, E. and Phillips, M. and Philippou, H. and Foley, J. and Mutch, N. and Ariëns, R. and Stringer, K. and Ricciardi, F. and Watissée, M. and Hughes, D. and Nathwani, A. and Riddell, A. and Patch, D. and Buckley, J. and De Neef, M. and Dimber, R. and Diaz-Garcia, C. and Patel, H. and Nandani, A. and Dissanayake, U. and Chadwick, N. and Alkhatip, A. and Watkinson, P. and Raith, E. and Singh, S. and Wolff, T. and Jha, R. and Brill, S. and Bakhai, A. and Evans, A. and Gilani, F. and Gomez, K.},
month = {sep},
year = {2023},
abstract = {Acute lung injury in COVID-19 results in diffuse alveolar damage with disruption of the alveolar-capillary barrier, coagulation activation, alveolar fibrin deposition and pulmonary capillary thrombi. Nebulized recombinant tissue plasminogen activator (rt-PA) has the potential to facilitate localized thrombolysis in the alveolar compartment and improve oxygenation. In this proof-of-concept safety study, adults with COVID-19-induced respiratory failure and a &lt;300 mmHg PaO2/FiO2(P/F) ratio requiring invasive mechanical ventilation (IMV) or non-invasive respiratory support (NIRS) received nebulized rt-PA in two cohorts (C1 and C2), alongside standard of care, between 23 April–30 July 2020 and 21 January–19 February 2021, respectively. Matched historical controls (MHC; n = 18) were used in C1 to explore efficacy. Safety co-primary endpoints were treatment-related bleeds and &lt;1.0–1.5 g/L fibrinogen reduction. A variable dosing strategy with clinical efficacy endpoint and minimal safety concerns was determined in C1 for use in C2; patients were stratified by ventilation type to receive 40–60 mg rt-PA daily for ≤14 days. Nine patients in C1 (IMV, 6/9; NIRS, 3/9) and 26 in C2 (IMV, 12/26; NIRS, 14/26) received nebulized rt-PA for a mean (SD) of 6.7 (4.6) and 9.1(4.6) days, respectively. Four bleeds (one severe, three mild) in three patients were considered treatment related. There were no significant fibrinogen reductions. Greater improvements in mean P/F ratio from baseline to study end were observed in C1 compared with MHC (C1; 154 to 299 vs. MHC; 154 to 212). In C2, there was no difference in the baseline P/F ratio of NIRS and IMV patients. However, a larger improvement in the P/F ratio occurred in NIRS patients (NIRS; 126 to 240 vs. IMV; 120 to 188) and fewer treatment days were required (NIRS; 7.86 vs. IMV; 10.5). Nebulized rt-PA appears to be well-tolerated, with a trend towards improved oxygenation, particularly in the NIRS group. Randomized clinical trials are required to demonstrate the clinical effect significance and magnitude.},
volume = {12},
issue = {18},
journal = {Journal of Clinical Medicine},
publisher = {MDPI},
url = {https://doi.org/10.3390/jcm12185848},
}
